Literature DB >> 24452472

β-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma.

Ian C Clift1, Adebowale O Bamidele, Christie Rodriguez-Ramirez, Kimberly N Kremer, Karen E Hedin.   

Abstract

CXC chemokine receptor 4 (CXCR4) is a G protein-coupled receptor (GPCR) located on the cell surface that signals upon binding the chemokine stromal derived factor-1 (SDF-1; also called CXCL 12). CXCR4 promotes neuroblastoma proliferation and chemotaxis. CXCR4 expression negatively correlates with prognosis and drives neuroblastoma growth and metastasis in mouse models. All functions of CXCR4 require its expression on the cell surface, yet the molecular mechanisms that regulate CXCR4 cell-surface levels in neuroblastoma are poorly understood. We characterized CXCR4 cell-surface regulation in the related SH-SY5Y and SK-N-SH human neuroblastoma cell lines. SDF-1 treatment caused rapid down-modulation of CXCR4 in SH-SY5Y cells. Pharmacologic activation of protein kinase C similarly reduced CXCR4, but via a distinct mechanism. Analysis of CXCR4 mutants delineated two CXCR4 regions required for SDF-1 treatment to decrease cell-surface CXCR4 in neuroblastoma cells: the isoleucine-leucine motif at residues 328 and 329 and residues 343-352. In contrast, and unlike CXCR4 regulation in other cell types, serines 324, 325, 338, and 339 were not required. Arrestin proteins can bind and regulate GPCR cell-surface expression, often functioning together with kinases such as G protein-coupled receptor kinase 2 (GRK2). Using SK-N-SH cells which are naturally deficient in β-arrestin1, we showed that β-arrestin1 is required for the CXCR4 343-352 region to modulate CXCR4 cell-surface expression following treatment with SDF-1. Moreover, GRK2 overexpression enhanced CXCR4 internalization, via a mechanism requiring both β-arrestin1 expression and the 343-352 region. Together, these results characterize CXCR4 structural domains and β-arrestin1 as critical regulators of CXCR4 cell-surface expression in neuroblastoma. β-Arrestin1 levels may therefore influence the CXCR4-driven metastasis of neuroblastoma as well as prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452472      PMCID: PMC4170118          DOI: 10.1124/mol.113.089714

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  59 in total

1.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

2.  Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization.

Authors:  Giuseppe Bardi; Rajarshi Sengupta; Muhammad Z Khan; Jeegar P Patel; Olimpia Meucci
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

3.  G protein-coupled receptor kinase 5 phosphorylation of hip regulates internalization of the chemokine receptor CXCR4.

Authors:  Breann L Barker; Jeffrey L Benovic
Journal:  Biochemistry       Date:  2011-07-12       Impact factor: 3.162

4.  A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Authors:  H Geminder; O Sagi-Assif; L Goldberg; T Meshel; G Rechavi; I P Witz; A Ben-Baruch
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization.

Authors:  B Haribabu; R M Richardson; I Fisher; S Sozzani; S C Peiper; R Horuk; H Ali; R Snyderman
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

6.  CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation.

Authors:  Alex J Carlisle; Christopher A Lyttle; Rosalind Y Carlisle; John M Maris
Journal:  Mol Cancer       Date:  2009-12-22       Impact factor: 27.401

7.  Arrestin-2 interacts with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4.

Authors:  Deepali Bhandari; JoAnn Trejo; Jeffrey L Benovic; Adriano Marchese
Journal:  J Biol Chem       Date:  2007-10-18       Impact factor: 5.157

8.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.

Authors:  K Tachibana; S Hirota; H Iizasa; H Yoshida; K Kawabata; Y Kataoka; Y Kitamura; K Matsushima; N Yoshida; S Nishikawa; T Kishimoto; T Nagasawa
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

Review 9.  Agonist-selective mechanisms of GPCR desensitization.

Authors:  E Kelly; C P Bailey; G Henderson
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

10.  Comprehensive cytogenomic profile of the in vitro neuronal model SH-SY5Y.

Authors:  Mohammed Yusuf; Kay Leung; Keith J Morris; Emanuela V Volpi
Journal:  Neurogenetics       Date:  2012-12-09       Impact factor: 2.660

View more
  17 in total

1.  Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor.

Authors:  Shannon R Hinson; Ian C Clift; Ningling Luo; Thomas J Kryzer; Vanda A Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

2.  Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.

Authors:  Jonathan M Eby; Hazem Abdelkarim; Lauren J Albee; Abhishek Tripathi; Xianlong Gao; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak
Journal:  Mol Cell Biochem       Date:  2017-04-28       Impact factor: 3.396

3.  A Novel Role of Proline Oxidase in HIV-1 Envelope Glycoprotein-induced Neuronal Autophagy.

Authors:  Jui Pandhare; Sabyasachi Dash; Bobby Jones; Fernando Villalta; Chandravanu Dash
Journal:  J Biol Chem       Date:  2015-09-01       Impact factor: 5.157

4.  β-Arrestin2 mediates progression of murine primary myelofibrosis.

Authors:  Lindsay Am Rein; James W Wisler; Jihee Kim; Barbara Theriot; LiYin Huang; Trevor Price; Haeyoon Yang; Minyong Chen; Wei Chen; Dorothy Sipkins; Yuri Fedoriw; Julia Kl Walker; Richard T Premont; Robert J Lefkowitz
Journal:  JCI Insight       Date:  2017-12-21

5.  GRK2 mediates TCR-induced transactivation of CXCR4 and TCR-CXCR4 complex formation that drives PI3Kγ/PREX1 signaling and T cell cytokine secretion.

Authors:  Brittney A Dinkel; Kimberly N Kremer; Meagan R Rollins; Michael J Medlyn; Karen E Hedin
Journal:  J Biol Chem       Date:  2018-07-17       Impact factor: 5.157

6.  Cell size dependent migration of T-cells latently infected with HIV.

Authors:  Kathrin Bohn-Wippert; Roy D Dar
Journal:  J Life Sci (Westlake Village)       Date:  2020-03

7.  IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.

Authors:  Janani Panneerselvam; Jiankang Jin; Manish Shanker; Jason Lauderdale; Jonathan Bates; Qi Wang; Yan D Zhao; Stephen J Archibald; Timothy J Hubin; Rajagopal Ramesh
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

Review 8.  β-arrestin1 at the cross-road of endothelin-1 signaling in cancer.

Authors:  Laura Rosanò; Anna Bagnato
Journal:  J Exp Clin Cancer Res       Date:  2016-07-29

Review 9.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases.

Authors:  Giovanni Bernardini; Fabrizio Antonangeli; Valentina Bonanni; Angela Santoni
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

10.  Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.

Authors:  Roberta Cianfrocca; Piera Tocci; Laura Rosanò; Valentina Caprara; Rosanna Sestito; Valeriana Di Castro; Anna Bagnato
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.